Celltrion Arbitral Award
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 1.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shilpa Medicare has received a favorable arbitral award in its long-running commercial dispute with South Korea's Celltrion Inc. The arbitration tribunal ruled that Celltrion's termination of their biologics manufacturing and supply arrangement was wrongful and amounted to a breach of the agreement. The tribunal upheld Shilpa Medicare's contractual rights related to the manufacture and supply of biosimilar products including trastuzumab. Specific financial relief or damages granted are still being evaluated and will be disclosed separately. This marks a significant legal victory for the company in a dispute that had been an overhang on its biologics business.
Positive for shareholders — the company has won a major international arbitration, strengthening its legal position and potentially entitling it to damages, compensation, or restored contractual benefits from Celltrion.